Brief: Adaptimmune Therapeutics Revenue For Q4 Was $11.0 Million

Adaptimmune Therapeutics

06/03/2023 12:08

March 6 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * ADAPTIMMUNE THERAPEUTICS PLC - REVENUE FOR THE FOURTH
QUARTER
ENDED DECEMBER 31, 2022 WAS $11.0 MILLION
    * ADAPTIMMUNE THERAPEUTICS PLC - ADAPTIMMUNE WILL ADVANCE
ITS
WHOLLY OWNED OPTIMIZED PRAME TCR TO BE IND-READY IN 2023
    * ADAPTIMMUNE THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.03
    * ADAPTIMMUNE THERAPEUTICS PLC - BLA SUBMISSION INITIATED
FOR
AFAMI-CEL, WITH AIM TO COMPLETE IN MID-2023
    * ADAPTIMMUNE THERAPEUTICS PLC- ON MARCH 2 CO AND UNIVERSAL
CELLS
AGREED TO TERMINATION OF COLLABORATION AND LICENSE AGREEMENT
DATED JAN 13, 2020
    * ADAPTIMMUNE THERAPEUTICS PLC -  BELIEVES ITS EXISTING
CASH, CASH
EQUIVALENTS & MARKETABLE SECURITIES WILL FUND CO'S CURRENT
OPERATIONS INTO EARLY 2025

Source text for Eikon:  ID: 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))